Related Experiment Video
Updated: Aug 8, 2026

RhoC GTPase Activation Assay
Published on: August 22, 2010
Cellular stability of Rho-GTPases glucosylated by Clostridium difficile toxin B
Harald Genth1, Johannes Huelsenbeck, Birgit Hartmann
1Department of Toxicology, Hannover Medical School, Germany. genth.harald@mh-hannover.de
Abstract:
Mono-glucosylation of Rho, Rac, and Cdc42 by Clostridium difficile toxin B (TcdB) induces changes of actin dynamics and apoptosis. When fibroblasts were treated with TcdB, an apparent decrease of the cellular Rac1 level was observed when applying anti-Rac1(Mab 102). This decrease was not based on degradation as inhibition of the proteasome by lactacystin did not stabilise cellular Rac1 levels. The application of anti-Rac1 (Mab 23A8) showed that the cellular Rac1 level slightly increased in TcdB-treated fibroblasts; thus, the apparent loss of cellular Rac1 was not due to degradation but due to impaired recognition of glucosylated Rac1 by anti-Rac1 (Mab 102). In contrast, recognition of RhoA by anti-RhoA (Mab 26C4) and Cdc42 by anti-Cdc42 (Mab 44) was not altered by glucosylation; a transient decrease of cellular RhoA and Cdc42 in TcdB-treated fibroblasts was indeed due to proteasomal degradation, as inhibition of the proteasome by lactacystin stabilised both cellular RhoA and Cdc42 levels. The finding that the apparent decrease of Rac1 reflects Rac1 glucosylation offers a valuable tool to determine Rac1 glucosylation.
Insights
Clostridium difficile toxin B (TcdB) modifies Rho, Rac, and Cdc42 proteins. An apparent Rac1 decrease indicates its glucosylation, not degradation, offering a new detection method.
Area of Science:
- Cellular Biology
- Molecular Microbiology
- Toxicology
Background:
- Clostridium difficile toxin B (TcdB) modifies Rho GTPases, impacting actin dynamics and apoptosis.
- Understanding TcdB's specific effects on Rho, Rac, and Cdc42 is crucial for cell biology research.
Purpose of the Study:
- To investigate the mechanism behind the apparent decrease in cellular Rac1 levels after TcdB treatment.
- To differentiate between protein degradation and modification as causes for altered protein levels.
- To establish a method for detecting Rac1 glucosylation.
Main Methods:
- Treatment of fibroblasts with TcdB.
- Inhibition of proteasomal degradation using lactacystin.
- Western blot analysis using different antibodies (Mab 102, Mab 23A8 for Rac1; Mab 26C4 for RhoA; Mab 44 for Cdc42).
Main Results:
- Apparent Rac1 decrease upon TcdB treatment was due to impaired antibody recognition of glucosylated Rac1, not degradation.
- Proteasome inhibition did not stabilize Rac1 levels, confirming it's not degraded.
- RhoA and Cdc42 levels transiently decreased due to proteasomal degradation, which was reversed by lactacystin.
Conclusions:
- The apparent loss of Rac1 is a direct indicator of its glucosylation by TcdB.
- This finding provides a novel method for assessing Rac1 glucosylation in cellular studies.
- TcdB differentially affects Rho GTPases, with Rac1 undergoing glucosylation and RhoA/Cdc42 undergoing degradation.
More Related Videos
Related Concept Videos
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
GPCRs Regulate Adenylyl Cylase Activity
Two...
The Ras Gene
Ras is a superfamily...
Stringent Response in E. coli
Rab Proteins
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...
Microtubule Instability

